grey
space
About Us
      Technology      Investors      News / Events      Contact
Advanced Proteome Therapeutics

About Us

Management / Directors

Dr. Allen (Alexander) Krantz,  President, CEO and Director
Allen Krantz, the founder of Advanced Proteome Therapeutics , has had an extensive career in academia and industry. From 1968 to 1974, he was a member of the Faculty of Chemistry at the State University of New York at Stony Brook and from 1974 to 1981 he held appointments in both the Department of Chemistry and the Department of Pharmacological Sciences in the Medical School in that same institution. From 1981 to 1992, Dr. Krantz was Director of Research at Syntex Research Canada and held Adjunct Professorships during this period at the Universities of Toronto and Guelph. In 1992, Dr. Krantz was appointed Vice-President of Research at Syntex and held the title of Distinguished Scientist from 1993-1994. From 1994 to 1997, Dr. Krantz served as Executive Vice President of Research at RedCell, Inc., the forerunner of ConjuChem, (TSX: CJC), and served as the Directeur Scientifique of the European office in France during the same period. Dr. Krantz was responsible for transforming the company's program to a practical focal point on human serum albumin as a carrier of drugs. He is also a Founder, and served as the inaugural President of Pharmena North America Incorporated, a privately held, biotechnology company. Dr. Krantz obtained his Masters of Science and Ph.D. degrees from Yale University. 

Dr. Gary Hayes, MD - Director
Dr Hayes graduated from the University of Manitoba in 1978. He has 27 years in clinical Family Practice, and has been a medical advisor to numerous companies and sports teams that utilize his extensive knowledge of therapeutics. Dr Hayes has also been active as a Director of several publicly traded companies.

Jean Bellin, Director
Jean Bellin has more than 25 years experience in the pharmaceutical industry, including sales, marketing, business development, mergers and acquisitions, and general management – both domestic and international.  He began his pharmaceutical industry career with 12 years at Eli Lilly & Company, holding positions in sales, marketing and general management in Brazil, the US, the Scandinavian countries and Italy.  He then founded and served as Managing Director of DuPont Pharma Italy.  In 1993, Mr. Bellin became the head of the international division of UCB, a $2 billion publicly traded, biopharmaceutical group based in Brussels, Belgium.  There he managed the pharmaceutical subsidiaries in the US, Canada, South America, Japan, China and Southeast Asia.  Later he managed the osteohealth and animal health divisions of Sankyo Pharmaceuticals Company Ltd., then the second largest pharmaceutical company in Japan. He was also previously the CEO of Mountain View Pharmaceuticals Inc., a California-based biopharmaceutical company where the PEGylation of therapeutic proteins was a major focus. He is currently the President of Metagenics, a leading manufacturer and distributor of medical foods and nutraceuticals. Mr. Bellin received his bachelor’s degree in Economic, Political and Social Sciences from the Universitaires Saint Louis in Brussels and a license in applied economic sciences from the Catholique de Louvain in Belgium.

Kenneth C Phillippe, B. Comm, CA.
Mr. Phillippe is a Chartered Accountant with over 25 years experience working with public companies in the capacities of director, officer, financial advisor or consultant. Mr. Phillippe obtained a Bachelor of Commerce degree from the University of British Columbia in 1976. He articled with Thorne Riddell (now KPMG) and obtained his professional accounting designation in 1981. In 1982 Mr. Phillippe established his own accounting practice. Between February 2000 and August 2005 he served in various positions including director, officer and chair of the audit committee of Urodynamix Technologies Ltd.(TSX – (URO.V)., a Vancouver-based medical device company. Between January and December 2006 Mr. Phillippe served as chief financial officer of Columbia Goldfields Ltd. (TSX - (GOL.TO) / OTCBB –(CGDF)), a junior gold mining company that is also a reporting company under the US Exchange Act. In addition, Mr. Phillippe has served as the Secretary, Treasurer, Chief Financial Officer and Principal Accounting Officer of Amazon Goldsands Ltd.(OTCBB – (AZNG)), from  October 2006 to September 2008 and  Constitution Mining Corp (OTCC - (CMIN)) from  December 2007 to September 2008., both reporting companies under the US Exchange Act. Since March 2006 Mr. Phillippe has served as Chief Financial Officer of Exchequer Resource Corp. (TSX/NEX – (EXQ.H)). Since October 2006, Mr. Phillippe has served as Chief Financial Officer and Secretary of Bold Ventures Inc. (TSX – (BOL.V)), which was listed on the TSX-V on October 29, 2007.

 

space
 
Website and branding by NextPhase Strategy